tirzepatide europe approval Lilly's new drug Mounjaro (tirzepatide ) wins US FDA Tirzepatide — EU Status
Description
This trend is everywhere right now
People with obesity and insulin resistance typically have poor metabolic flexibility
Overall, the degree of heterogenity for these analyses can be considered negligible or low
It does not replace medical advice from a healthcare professional
Sumithran, P., et al
Taken together, these findings help explain why weight regain after stopping tirzepatide is common
